Pacific Edge Biotechnology predicts healthier revenue flows this year as its first products near commercial release after four years of research and development.
The fledgling Dunedin biomedical company reported a net loss for the year to March 31 of $2.85 million, in line with a budgeted loss of that amount.
Unlock all articles by subscribing to this international offer
All-Access + BusinessDesk Weekly
Herald Premium, Viva Premium, The Listener & BusinessDesk
Pay just
$10
$2
per week
Already a subscriber? Sign in here
Or
